

Andrzej GÅ³rski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2808417/publications.pdf>

Version: 2024-02-01

172
papers

7,020
citations

50276

46
h-index

71685

76
g-index

181
all docs

181
docs citations

181
times ranked

4550
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Aspects of Phage Therapy. <i>Advances in Virus Research</i> , 2012, 83, 73-121.	2.1	274
2	Bacteriophage Endolysins as a Novel Class of Antibacterial Agents. <i>Experimental Biology and Medicine</i> , 2006, 231, 366-377.	2.4	271
3	The Phage Therapy Paradigm: PrÅt-ÅPorter or Sur-mesure?. <i>Pharmaceutical Research</i> , 2011, 28, 934-937.	3.5	249
4	Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury. <i>Cell Transplantation</i> , 2013, 22, 1591-1612.	2.5	238
5	Phage as a Modulator of Immune Responses. <i>Advances in Virus Research</i> , 2012, 83, 41-71.	2.1	206
6	Mammalian Host-Versus-Phage immune response determines phage fate in vivo. <i>Scientific Reports</i> , 2015, 5, 14802.	3.3	201
7	Bacteriophage translocation. <i>FEMS Immunology and Medical Microbiology</i> , 2006, 46, 313-319.	2.7	192
8	Phage Neutralization by Sera of Patients Receiving Phage Therapy. <i>Viral Immunology</i> , 2014, 27, 295-304.	1.3	179
9	Quality and Safety Requirements for Sustainable Phage Therapy Products. <i>Pharmaceutical Research</i> , 2015, 32, 2173-2179.	3.5	176
10	The potential role of endogenous bacteriophages in controlling invading pathogens. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 511-519.	5.4	137
11	Immunogenicity Studies of Proteins Forming the T4 Phage Head Surface. <i>Journal of Virology</i> , 2014, 88, 12551-12557.	3.4	135
12	Bacteriophage Procurement for Therapeutic Purposes. <i>Frontiers in Microbiology</i> , 2016, 7, 1177.	3.5	125
13	Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases. <i>Frontiers in Microbiology</i> , 2016, 7, 1515.	3.5	120
14	Phages and immunomodulation. <i>Future Microbiology</i> , 2017, 12, 905-914.	2.0	117
15	Bacteriophages in the gastrointestinal tract and their implications. <i>Gut Pathogens</i> , 2017, 9, 44.	3.4	114
16	Characterising the biology of novel lytic bacteriophages infecting multidrug resistant <i>Klebsiella pneumoniae</i> . <i>Virology Journal</i> , 2013, 10, 100.	3.4	112
17	Phage therapy: Current status and perspectives. <i>Medicinal Research Reviews</i> , 2020, 40, 459-463.	10.5	102
18	Phage Therapy: What Have We Learned?. <i>Viruses</i> , 2018, 10, 288.	3.3	101

#	ARTICLE	IF	CITATIONS
19	Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. <i>Wound Repair and Regeneration</i> , 2013, 21, 595-603.	3.0	92
20	Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy. <i>Frontiers in Microbiology</i> , 2016, 7, 1681.	3.5	92
21	Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. <i>Transplantation Proceedings</i> , 2003, 35, 1385-1386.	0.6	86
22	T4 Phage Tail Adhesin Gp12 Counteracts LPS-Induced Inflammation In Vivo. <i>Frontiers in Microbiology</i> , 2016, 7, 1112.	3.5	83
23	Factors determining phage stability/activity: challenges in practical phage application. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 583-606.	4.4	82
24	Effects of bacteriophages on free radical production and phagocytic functions. <i>Medical Microbiology and Immunology</i> , 2006, 195, 143-150.	4.8	81
25	Facing Antibiotic Resistance: Staphylococcus aureus Phages as a Medical Tool. <i>Viruses</i> , 2014, 6, 2551-2570.	3.3	80
26	T4 Phage and Its Head Surface Proteins Do Not Stimulate Inflammatory Mediator Production. <i>PLoS ONE</i> , 2013, 8, e71036.	2.5	79
27	Bacteriophage therapy for the treatment of infections. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 766-74.	2.3	79
28	Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. <i>Virus Research</i> , 2008, 131, 233-242.	2.2	78
29	Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis – case report. <i>Folia Microbiologica</i> , 2009, 54, 457-461.	2.3	78
30	Preparation of endotoxin-free bacteriophages. <i>Cellular and Molecular Biology Letters</i> , 2004, 9, 253-9.	7.0	72
31	Antiphage activity of sera during phage therapy in relation to its outcome. <i>Future Microbiology</i> , 2017, 12, 109-117.	2.0	71
32	New insights into the possible role of bacteriophages in host defense and disease. <i>Medical Immunology</i> , 2003, 2, 2.	2.1	68
33	Is phage therapy acceptable in the immunocompromised host?. <i>International Journal of Infectious Diseases</i> , 2008, 12, 466-471.	3.3	66
34	Bacteriophages and Lysins in Biofilm Control. <i>Virologica Sinica</i> , 2020, 35, 125-133.	3.0	66
35	In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections. <i>Journal of Medical Microbiology</i> , 2014, 63, 1055-1065.	1.8	64
36	Phage-Phagocyte Interactions and Their Implications for Phage Application as Therapeutics. <i>Viruses</i> , 2017, 9, 150.	3.3	62

#	ARTICLE	IF	CITATIONS
37	Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. <i>BioDrugs</i> , 2021, 35, 255-280.	4.6	62
38	Phage Therapy: Towards a Successful Clinical Trial. <i>Antibiotics</i> , 2020, 9, 827.	3.7	59
39	Immunomodulating activity of heparin. <i>FASEB Journal</i> , 1991, 5, 2287-2291.	0.5	58
40	Successful eradication of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) intestinal carrier status in a healthcare worker – Case report. <i>Folia Microbiologica</i> , 2006, 51, 236-238.	2.3	57
41	A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. <i>Clinical and Experimental Medicine</i> , 2009, 9, 303-312.	3.6	53
42	Bacteriophages and cancer. <i>Archives of Microbiology</i> , 2010, 192, 315-320.	2.2	53
43	The perspectives of the application of phage therapy in chronic bacterial prostatitis. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 60, 99-112.	2.7	51
44	Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80. <i>Frontiers in Microbiology</i> , 2017, 08, 467.	3.5	50
45	Perspectives of Phage Therapy in Non-bacterial Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 3306.	3.5	49
46	Induction of Phage-Specific Antibodies by Two Therapeutic Staphylococcal Bacteriophages Administered per os. <i>Frontiers in Immunology</i> , 2019, 10, 2607.	4.8	48
47	Hoc protein regulates the biological effects of T4 phage in mammals. <i>Archives of Microbiology</i> , 2007, 187, 489-498.	2.2	47
48	Phage Therapy in Poland – a Centennial Journey to the First Ethically Approved Treatment Facility in Europe. <i>Frontiers in Microbiology</i> , 2020, 11, 1056.	3.5	44
49	Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. <i>Postepy Higieny i Medycyny Doswiadczalnej</i> , 2007, 61, 461-5.	0.1	43
50	Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13391.	1.7	42
51	Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. <i>Immunology Letters</i> , 2008, 116, 24-32.	2.5	40
52	Phages targeting infected tissues: novel approach to phage therapy. <i>Future Microbiology</i> , 2015, 10, 199-204.	2.0	40
53	Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with <i>Staphylococcus aureus</i> . <i>BMC Microbiology</i> , 2009, 9, 169.	3.3	39
54	The Effect of Bacteriophage Preparations on Intracellular Killing of Bacteria by Phagocytes. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	2.2	39

#	ARTICLE	IF	CITATIONS
55	<i>In Vivo</i> Studies on the Influence of Bacteriophage Preparations on the Autoimmune Inflammatory Process. <i>BioMed Research International</i> , 2017, 2017, 1-9.	1.9	39
56	Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far. <i>Journal of Biomedical Science</i> , 2022, 29, 23.	7.0	39
57	Bacterial viruses against viruses pathogenic for man?. <i>Virus Research</i> , 2005, 110, 1-8.	2.2	38
58	Ethics review in compassionate use. <i>BMC Medicine</i> , 2017, 15, 136.	5.5	38
59	Effect of phage therapy on the turnover and function of peripheral neutrophils. <i>FEMS Immunology and Medical Microbiology</i> , 2002, 34, 135-138.	2.7	37
60	Molecular imaging of T4 phage in mammalian tissues and cells. <i>Bacteriophage</i> , 2014, 4, e28364.	1.9	37
61	The Potential of Phage Therapy in Sepsis. <i>Frontiers in Immunology</i> , 2017, 8, 1783.	4.8	35
62	Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. <i>Anticancer Research</i> , 2004, 24, 3991-5.	1.1	34
63	Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. <i>Clinical and Experimental Medicine</i> , 2009, 9, 93-100.	3.6	33
64	Taking Bacteriophage Therapy Seriously: A Moral Argument. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	31
65	Prospects of Phage Application in the Treatment of Acne Caused by <i>Propionibacterium acnes</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 164.	3.5	30
66	Bacteriophages engineered to display foreign peptides may become short-circulating phages. <i>Microbial Biotechnology</i> , 2019, 12, 730-741.	4.2	29
67	A novel approach for separating bacteriophages from other bacteriophages using affinity chromatography and phage display. <i>Scientific Reports</i> , 2013, 3, 3220.	3.3	27
68	Delivering phage therapy <i>per os</i> : benefits and barriers. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 167-179.	4.4	27
69	Phage Therapy: Beyond Antibacterial Action. <i>Frontiers in Medicine</i> , 2018, 5, 146.	2.6	27
70	The Potential of Phage Therapy in Bacterial Infections of the Eye. <i>Ophthalmologica</i> , 2009, 223, 162-165.	1.9	26
71	T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus <i>in vitro</i> . <i>Future Microbiology</i> , 2015, 10, 453-460.	2.0	26
72	Phages in the fight against COVID-19?. <i>Future Microbiology</i> , 2020, 15, 1095-1100.	2.0	26

#	ARTICLE	IF	CITATIONS
73	Human β -Defensin 2 and Its Postulated Role in Modulation of the Immune Response. <i>Cells</i> , 2021, 10, 2991.	4.1	26
74	Immunomodulatory action of human recombinant erythropoietin in man. <i>Immunology Letters</i> , 1993, 35, 271-275.	2.5	25
75	Compassionate use of unauthorized drugs: Legal regulations and ethical challenges. <i>European Journal of Internal Medicine</i> , 2019, 65, 12-16.	2.2	25
76	The Role of Antibiotic Resistant <i>A. baumannii</i> in the Pathogenesis of Urinary Tract Infection and the Potential of Its Treatment with the Use of Bacteriophage Therapy. <i>Antibiotics</i> , 2021, 10, 281.	3.7	25
77	Bacteriophages targeting intestinal epithelial cells: a potential novel form of immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 589-595.	5.4	24
78	Potential of Bacteriophages and Their Lysins in the Treatment of MRSA. <i>BioDrugs</i> , 2011, 25, 347-355.	4.6	23
79	Animal Models in the Evaluation of the Effectiveness of Phage Therapy for Infections Caused by Gram-Negative Bacteria from the ESKAPE Group and the Reliability of Its Use in Humans. <i>Microorganisms</i> , 2021, 9, 206.	3.6	23
80	Bacteriophage therapy in children: facts and prospects. <i>Medical Science Monitor</i> , 2008, 14, RA126-32.	1.1	23
81	Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment. <i>Future Microbiology</i> , 2014, 9, 861-869.	2.0	22
82	Selenium-containing polysaccharides from <i>Lentinula edodes</i> Biological activity. <i>Carbohydrate Polymers</i> , 2019, 223, 115078.	10.2	22
83	Phage-specific diverse effects of bacterial viruses on the immune system. <i>Future Microbiology</i> , 2019, 14, 1171-1174.	2.0	22
84	Specific and Selective Bacteriophages in the Fight against Multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Virologica Sinica</i> , 2019, 34, 347-357.	3.0	22
85	Prophylactic effect of bacteriophages on mice subjected to chemotherapy-induced immunosuppression and bone marrow transplant upon infection with <i>Staphylococcus aureus</i> . <i>Medical Microbiology and Immunology</i> , 2010, 199, 71-79.	4.8	21
86	The Effects of T4 and A3/R Phage Preparations on Whole-Blood Monocyte and Neutrophil Respiratory Burst. <i>Viral Immunology</i> , 2010, 23, 541-544.	1.3	21
87	Ethics codes and use of new and innovative drugs. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 501-507.	2.4	21
88	A3R Phage and <i>Staphylococcus aureus</i> Lysate Do Not Induce Neutrophil Degranulation. <i>Viruses</i> , 2017, 9, 36.	3.3	20
89	The fall and rise of phage therapy in modern medicine. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1115-1117.	3.1	19
90	Immune Response to Therapeutic Staphylococcal Bacteriophages in Mammals: Kinetics of Induction, Immunogenic Structural Proteins, Natural and Induced Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 639570.	4.8	19

#	ARTICLE	IF	CITATIONS
91	Fusion to cell-penetrating peptides will enable lytic enzymes to kill intracellular bacteria. <i>Medical Hypotheses</i> , 2010, 74, 164-166.	1.5	18
92	Phage Therapy in Prostatitis: Recent Prospects. <i>Frontiers in Microbiology</i> , 2018, 9, 1434.	3.5	18
93	Phages as a Cohesive Prophylactic and Therapeutic Approach in Aquaculture Systems. <i>Antibiotics</i> , 2020, 9, 564.	3.7	18
94	The Presence of Bacteriophages in the Human Body: Good, Bad or Neutral?. <i>Microorganisms</i> , 2020, 8, 2012.	3.6	18
95	Activity of Bacteriophages in Murine Tumor Models Depends on the Route of Phage Administration. <i>Oncology Research</i> , 2005, 15, 183-187.	1.5	16
96	The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration. <i>BMC Microbiology</i> , 2009, 9, 13.	3.3	16
97	Phage penetration of eukaryotic cells: practical implications. <i>Future Virology</i> , 2019, 14, 745-760.	1.8	16
98	Phage Prevalence in the Human Urinary Tract—Current Knowledge and Therapeutic Implications. <i>Microorganisms</i> , 2020, 8, 1802.	3.6	16
99	Phage therapy of wound-associated infections. <i>Folia Microbiologica</i> , 2022, 67, 193-201.	2.3	15
100	Bacteriophages provide regulatory signals in mitogen-induced murine splenocyte proliferation. <i>Cellular and Molecular Biology Letters</i> , 2003, 8, 699-711.	7.0	15
101	The Effects of T4 and A3/R Bacteriophages on Differentiation of Human Myeloid Dendritic Cells. <i>Frontiers in Microbiology</i> , 2016, 7, 1267.	3.5	14
102	Therapeutic potential of phages in autoimmune liver diseases. <i>Clinical and Experimental Immunology</i> , 2018, 192, 1-6.	2.6	14
103	Bacteriophage Interactions With Epithelial Cells: Therapeutic Implications. <i>Frontiers in Microbiology</i> , 2020, 11, 631161.	3.5	14
104	Phage therapy in allergic disorders?. <i>Experimental Biology and Medicine</i> , 2018, 243, 534-537.	2.4	13
105	Perspectives of Phage–Eukaryotic Cell Interactions to Control Epstein–Barr Virus Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 630.	3.5	13
106	Editorial: Advances in Phage Therapy: Present Challenges and Future Perspectives. <i>Frontiers in Microbiology</i> , 2021, 12, 701898.	3.5	13
107	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. , 2018, , 1-31.		13
108	Therapeutic Perspectives and Mechanistic Insights of Phage Therapy in Allogeneic Transplantation. <i>Transplantation</i> , 2021, 105, 1449-1458.	1.0	13

#	ARTICLE	IF	CITATIONS
109	Influence of Bacteriophage Preparations on Intracellular Killing of Bacteria by Human Phagocytes <i>in Vitro</i> . <i>Viral Immunology</i> , 2013, 26, 150-162.	1.3	12
110	Possible Use of Bacteriophages Active against <i>Bacillus anthracis</i> and Other <i>B. cereus</i> Group Members in the Face of a Bioterrorism Threat. <i>BioMed Research International</i> , 2014, 2014, 1-14.	1.9	12
111	Phages in Therapy and Prophylaxis of American Foulbrood – Recent Implications From Practical Applications. <i>Frontiers in Microbiology</i> , 2020, 11, 1913.	3.5	12
112	Natural and Induced Antibodies Against Phages in Humans: Induction Kinetics and Immunogenicity for Structural Proteins of PB1-Related Phages. <i>Phage</i> , 2020, 1, 91-99.	1.7	12
113	Legal regulations, ethical guidelines and recent policies to increase transparency of clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 679-686.	2.4	12
114	Temperate Bacteriophages – The Powerful Indirect Modulators of Eukaryotic Cells and Immune Functions. <i>Viruses</i> , 2021, 13, 1013.	3.3	11
115	A Thorough Synthesis of Phage Therapy Unit Activity in Poland – Its History, Milestones and International Recognition. <i>Viruses</i> , 2022, 14, 1170.	3.3	11
116	Microbiota in organ transplantation: An immunological and therapeutic conundrum?. <i>Cellular Immunology</i> , 2020, 351, 104080.	3.0	10
117	Enhanced T cells interactions with extracellular matrix proteins in infertile women with endometriosis. <i>Immunology Letters</i> , 2002, 81, 65-70.	2.5	9
118	The Rationale for Using Bacteriophage to Treat and Prevent Periprosthetic Joint Infections. <i>Frontiers in Microbiology</i> , 2020, 11, 591021.	3.5	9
119	Anti-phage serum antibody responses and the outcome of phage therapy. <i>Folia Microbiologica</i> , 2021, 66, 127-131.	2.3	9
120	Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections. <i>Antibiotics</i> , 2021, 10, 627.	3.7	9
121	LPS-Activated Monocytes Are Unresponsive to T4 Phage and T4-Generated <i>Escherichia coli</i> Lysate. <i>Frontiers in Microbiology</i> , 2016, 7, 1356.	3.5	8
122	Can phage therapy solve the problem of recalcitrant chronic rhinosinusitis?. <i>Future Microbiology</i> , 2017, 12, 1427-1442.	2.0	8
123	Phage Transplantation in Allotransplantation – Possible Treatment in Graft-Versus-Host Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 941.	4.8	8
124	Isolation and Characterization of Phages Active against <i>Paenibacillus</i> larvae Causing American Foulbrood in Honeybees in Poland. <i>Viruses</i> , 2021, 13, 1217.	3.3	8
125	Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections. <i>Antibiotics</i> , 2021, 10, 1030.	3.7	8
126	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. , 2021, 921-951.		8

#	ARTICLE	IF	CITATIONS
127	Two Newly Isolated Enterobacter-Specific Bacteriophages: Biological Properties and Stability Studies. <i>Viruses</i> , 2022, 14, 1518.	3.3	8
128	The effects of staphylococcal bacteriophage lysates on cancer cells in vitro. <i>Clinical and Experimental Medicine</i> , 2010, 10, 81-85.	3.6	7
129	Inhibitory Effects of Bacteriophage Preparations on Adenoviral Replication. <i>Intervirology</i> , 2019, 62, 37-44.	2.8	7
130	Ethics codes and medical decision making. <i>Patient Education and Counseling</i> , 2021, 104, 1312-1316.	2.2	7
131	Toll-Like Receptor 4 Gene Polymorphism C1196T in Polish Women with Postmenopausal Osteoporosis - Preliminary Investigation. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 239-243.	1.4	7
132	The effects of bacteriophages on the expression of genes involved in antimicrobial immunity*. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2019, 73, 414-420.	0.1	7
133	The concerted action of lactoferrin and bacteriophages in the clearance of bacteria in sublethally infected mice. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2008, 62, 42-6.	0.1	7
134	Low-dose heparin: a novel approach in immunosuppression. <i>Transplant International</i> , 1994, 7, 567-569.	1.6	6
135	Sepsis, Phages, and COVID-19. <i>Pathogens</i> , 2020, 9, 844.	2.8	6
136	Ethics framework for treatment use of investigational drugs. <i>BMC Medical Ethics</i> , 2020, 21, 116.	2.4	6
137	Anti-biofilm activity of bacteriophages and lysins in chronic rhinosinusitis. <i>Acta Virologica</i> , 2021, 65, 127-140.	0.8	6
138	The contribution of phage therapy to medical knowledge. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 238-240.	2.2	6
139	Use of a Regression Model to Study Host-Genomic Determinants of Phage Susceptibility in MRSA. <i>Antibiotics</i> , 2018, 7, 9.	3.7	5
140	Phage Therapy in Orthopaedic Implant-Associated Infections. , 2019, , 189-211.		5
141	The effects of T4 and A5/80 phages on the expression of immunologically important genes in differentiated Caco-2 cells*. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2020, 74, 371-376.	0.1	5
142	Journal Impact Factor and Self-Citations. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2021, 69, 21.	2.3	4
143	Identification of the Primary Structure of Selenium-Containing Polysaccharides Selectively Inhibiting T-Cell Proliferation. <i>Molecules</i> , 2021, 26, 5404.	3.8	4
144	Antitumor effect of combined treatment of mice with cytostatic agents and bacteriophage T4. <i>Anticancer Research</i> , 2009, 29, 2361-70.	1.1	4

#	ARTICLE	IF	CITATIONS
145	What Are the Potential Benefits of Using Bacteriophages in Periodontal Therapy?. <i>Antibiotics</i> , 2022, 11, 446.	3.7	4
146	Building the Prestige of <i>Archivum Immunologiae et Therapiae Experimentalis</i> : From a Little Known to an Internationally Recognized Journal. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 407-413.	2.3	3
147	<i>Bacteriophage Pharmacology and Immunology.</i> , 2021, , 295-339.		3
148	ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e26890.	4.3	3
149	Conflicts of interest in oncology expanded access studies. <i>International Journal of Cancer</i> , 2021, 149, 1809-1816.	5.1	3
150	The long-term outcome of renal transplantation. A 10-year follow-up of 765 recipients. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 476-483.	0.4	3
151	Immunological biomarkers and long term graft survival. Prospective follow-up of 457 kidney transplant recipients. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 178-183.	0.4	3
152	<i>Humoral Immune Response to Phage-Based Therapeutics.</i> , 2019, , 123-143.		3
153	Influence of bacteriophage preparations on migration of HL-60 leukemia cells in vitro. <i>Anticancer Research</i> , 2013, 33, 1569-74.	1.1	3
154	AITE Celebrates Its 70th Year of Publication (1953–2022). <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, 1.	2.3	3
155	Expanded access: growing importance to public health. <i>Journal of Epidemiology and Community Health</i> , 2018, 72, 557-558.	3.7	2
156	Structure of Post-Transplant Care in a Single Transplant Center. <i>Annals of Transplantation</i> , 2016, 21, 194-199.	0.9	2
157	<i>Bacteriophage Pharmacology and Immunology.</i> , 2018, , 1-45.		2
158	Bronisława Fejgin (1883–1943): Forgotten Important Contributor to International Microbiology and Phage Therapy. <i>Antibiotics</i> , 2021, 10, 1353.	3.7	2
159	The ethics of intellectual property rights in biomedicine and biotechnology: An introduction. <i>Science and Engineering Ethics</i> , 2005, 11, 4-6.	2.9	1
160	Reply to “Innovation and off-label use, the French case and more” by Brailion and Lexchin. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2448-2449.	2.4	1
161	The preliminary association study of osteopontin 707 C/T polymorphism with systemic lupus erythematosus in a Polish population. <i>Postepy Dermatologii I Alergologii</i> , 2020, 37, 190-194.	0.9	1
162	Public availability of results of ClinicalTrials.gov-registered expanded access studies. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	1

#	ARTICLE	IF	CITATIONS
163	Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunology and Medical Microbiology, 2002, 34, 135-138.	2.7	1
164	Nec Soli Cedit (article dedicated to Professor Ludwik Hirszfeld). Postepy Higieny I Medycyny Doswiadczalnej, 2005, 59, 570-2.	0.1	1
165	Extracellular matrix proteins dependent apoptosis of T Cells in women with a history of recurrent spontaneous abortion. American Journal of Reproductive Immunology, 2002, 48, 151-151.	1.2	0
166	Introduction to the proceedings of an international conference Placebo: Its action and place in health research today Warsaw, Poland, 12-13 April, 2003. Science and Engineering Ethics, 2004, 10, 3-4.	2.9	0
167	The Role of the Virome in the Gut-Liver Axis. , 2019, , 121-131.		0
168	Ethics of Phage Therapy. , 2019, , 379-385.		0
169	Polish Contribution to the Advancement of Phage Treatment in Humans. , 2020, , .		0
170	The responsible conduct of basic and clinical research. Science and Engineering Ethics, 2006, 12, 3-4.	2.9	0
171	Placebo: its action and place in health research today. Science and Engineering Ethics, 2004, 10, 3-4.	2.9	0
172	My remembrance of Professor Tadeusz Orłowski. , 2009, 119, 289-91.		0